Genetic markers for prediction of treatment outcomes in ovarian cancer

Research output: Contribution to journalArticle

Abstract

Drug resistance in epithelial ovarian cancer (EOC) limits the efficacy of therapies for this malignancy. This phenomenon might be partially explained by strong inter-individual genomic heterogeneity. Single nucleotide polymorphisms (SNPs) located in specific genes involved in platinum-based drugs inactivation and the metabolism and extrusion of taxanes could be relevant in terms of drugs response prediction. In this paper, we review candidates for genetic markers of treatment outcomes in ovarian cancer. Although an association between SNPs and response to chemotherapy has been detected in several studies, no clear conclusions can be drawn because of conflicting results. Genetic variants in determining response to chemotherapy and clinical outcome need to be clarified in EOC to allow stratification of patients, which would help optimize therapy.

Original languageEnglish
Pages (from-to)401-410
Number of pages10
JournalPharmacogenomics Journal
Volume14
Issue number5
DOIs
Publication statusPublished - Oct 11 2014

Fingerprint

Genetic Markers
Ovarian Neoplasms
Single Nucleotide Polymorphism
Drug Therapy
Taxoids
Platinum
Drug Resistance
Pharmaceutical Preparations
Therapeutics
Genes
Neoplasms
Ovarian epithelial cancer

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics
  • Medicine(all)

Cite this

Genetic markers for prediction of treatment outcomes in ovarian cancer. / Caiola, E.; Broggini, M.; Marabese, M.

In: Pharmacogenomics Journal, Vol. 14, No. 5, 11.10.2014, p. 401-410.

Research output: Contribution to journalArticle

@article{5b3fe4fb3a9748e3b1f6432e967ceb24,
title = "Genetic markers for prediction of treatment outcomes in ovarian cancer",
abstract = "Drug resistance in epithelial ovarian cancer (EOC) limits the efficacy of therapies for this malignancy. This phenomenon might be partially explained by strong inter-individual genomic heterogeneity. Single nucleotide polymorphisms (SNPs) located in specific genes involved in platinum-based drugs inactivation and the metabolism and extrusion of taxanes could be relevant in terms of drugs response prediction. In this paper, we review candidates for genetic markers of treatment outcomes in ovarian cancer. Although an association between SNPs and response to chemotherapy has been detected in several studies, no clear conclusions can be drawn because of conflicting results. Genetic variants in determining response to chemotherapy and clinical outcome need to be clarified in EOC to allow stratification of patients, which would help optimize therapy.",
author = "E. Caiola and M. Broggini and M. Marabese",
year = "2014",
month = "10",
day = "11",
doi = "10.1038/tpj.2014.32",
language = "English",
volume = "14",
pages = "401--410",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Genetic markers for prediction of treatment outcomes in ovarian cancer

AU - Caiola, E.

AU - Broggini, M.

AU - Marabese, M.

PY - 2014/10/11

Y1 - 2014/10/11

N2 - Drug resistance in epithelial ovarian cancer (EOC) limits the efficacy of therapies for this malignancy. This phenomenon might be partially explained by strong inter-individual genomic heterogeneity. Single nucleotide polymorphisms (SNPs) located in specific genes involved in platinum-based drugs inactivation and the metabolism and extrusion of taxanes could be relevant in terms of drugs response prediction. In this paper, we review candidates for genetic markers of treatment outcomes in ovarian cancer. Although an association between SNPs and response to chemotherapy has been detected in several studies, no clear conclusions can be drawn because of conflicting results. Genetic variants in determining response to chemotherapy and clinical outcome need to be clarified in EOC to allow stratification of patients, which would help optimize therapy.

AB - Drug resistance in epithelial ovarian cancer (EOC) limits the efficacy of therapies for this malignancy. This phenomenon might be partially explained by strong inter-individual genomic heterogeneity. Single nucleotide polymorphisms (SNPs) located in specific genes involved in platinum-based drugs inactivation and the metabolism and extrusion of taxanes could be relevant in terms of drugs response prediction. In this paper, we review candidates for genetic markers of treatment outcomes in ovarian cancer. Although an association between SNPs and response to chemotherapy has been detected in several studies, no clear conclusions can be drawn because of conflicting results. Genetic variants in determining response to chemotherapy and clinical outcome need to be clarified in EOC to allow stratification of patients, which would help optimize therapy.

UR - http://www.scopus.com/inward/record.url?scp=84927176517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927176517&partnerID=8YFLogxK

U2 - 10.1038/tpj.2014.32

DO - 10.1038/tpj.2014.32

M3 - Article

C2 - 25001881

AN - SCOPUS:84927176517

VL - 14

SP - 401

EP - 410

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 5

ER -